Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Figure Technology Solutions Inc. Class A Common Stock (FIGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Figure Technology Solutions Inc. Class A Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.29 (market cap $2.81B), while Figure Technology Solutions Inc. Class A Common Stock trades at $25.38 (market cap $5.62B). The key difference: Figure Technology Solutions Inc. Class A Common Stock is far larger — about 2× Dyne Therapeutics Inc. Common Stock's market cap, and Figure Technology Solutions Inc. Class A Common Stock is more actively traded (6,052,510 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Figure Technology Solutions Inc. Class A Common Stock for 6 Days on average.
| DYN | FIGR | |
|---|---|---|
Market Cap | $2.81B | $5.62B |
Volume | 2,195,902 | 6,052,510 |
Sector | Health | Financials |
52-Week High | $26.78 | $73.91 |
52-Week Low | $14.60 | $24.91 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.13B | $5.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FIGR trades at $27.25, down 4.25% over 24 hours, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS beat expectations at $0.37, revenue grew to $509.30M in 2025, and net income margin improved to 33.83% in 2026. Recent news highlights the Kiavi acquisition and partnership with Sierra to enhance AI-driven lending capabilities, supporting growth in loan volumes.
Wall Street maintains a bullish outlook with a consensus price target of $50.00, implying significant upside. However, risks include recent earnings misses in Q4 2025 and Q1 2026, negative operating cash flow projected for 2026, and competitive pressures in the lending infrastructure space. The stock's high P/E of 28.52 warrants caution amid growth execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Figure Technology Solutions Inc. Class A Common Stock
Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.
Read more on FIGR →
